Key result
SGLT-2 inhibitors significantly reduced the risk of cardiovascular death or HF hospitalization by 23% and decreased adverse events (OR 0.78; 95% CI 0.69-0.88) compared to control.
Why the study?
The study was conducted to investigate the efficacy and safety of SGLT-2 inhibitors in patients with HF and T2DM.
Do SGLT-2 inhibitors improve clinical outcomes, cardiac function, and quality of life in patients with heart failure and type 2 diabetes mellitus?
Comparison
SGLT-2 inhibitors vs control
Design
Meta-analysis
Authors
Loading...
Supports SGLT2 inhibitor use in HF with T2DM to cut mortality and HF events; confirms benefits in Level 1 meta-analysis of trials.
Meta-Analysis (n=9,509)
Do SGLT-2 inhibitors improve clinical outcomes, cardiac function, and quality of life in patients with heart failure and type 2 diabetes mellitus?
Odds Ratio: 0.78 (95% CI 0.69–0.88)
SGLT-2 inhibitors significantly reduce mortality and heart failure hospitalizations while improving cardiac function and quality of life in patients with concurrent heart failure and type 2 diabetes mellitus.
Yao et al. (2025) conducted a meta-analysis in Heart failure and type 2 diabetes mellitus (n=9,509). SGLT-2 inhibitors vs. Control group was evaluated on Adverse events (OR 0.78, 95% CI 0.69-0.88). SGLT-2 inhibitors significantly reduced the risk of cardiovascular death or HF hospitalization by 23% and decreased adverse events (OR 0.78; 95% CI 0.69-0.88) compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: